Skip to content
Nonprofiteer
← THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

Form 990 for tax year 2024

Filed by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC.

Totals

Total revenue
$29,101,414
Total expenses
$35,604,337
Contributions and grants received
$24,100,727
Grants paid
$6,080,876
Program service revenue
$2,261,716
Investment income
$2,238,351
Other revenue
$500,620
Total assets, end of year
$66,397,148
Total liabilities, end of year
$16,374,755
Net assets or fund balances, end of year
$50,022,393
Program services expenses (Part IX)
$29,021,484
Management and general expenses
$1,202,727
Fundraising expenses
$5,380,126
Program service expenses (Part III)
$29,021,484

Program services were 81.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e , Government grants (contributions)

    $96,720

  • 1f , All other contributions, gifts and grants

    $24,004,007

  • 1g , Noncash contributions included above

    $416,902

  • 2a , Program service revenue: RESEARCH & CLINICAL TRIALS

    total $2,261,716 · related or exempt $2,261,716

  • 3 , Investment income

    total $1,580,287 · excluded $1,580,287

  • 5 , Royalties

    total $500,620 · related or exempt $500,620

  • 7a , Gross sales of assets other than inventory

    securities $100,370,765

  • 7b , Less cost or other basis and sales expenses

    securities $99,712,701

  • 7c , Gain or loss

    securities $658,064

  • 7d , Net gain or loss

    total $658,064 · excluded $658,064

Functional expenses

Part IX, the statement of functional expenses.

  • 1 , Grants to domestic organizations and governments

    total $5,330,876 · program services $5,330,876

  • 3 , Grants to foreign organizations and individuals

    total $750,000 · program services $750,000

  • 5 , Compensation of officers, directors and key employees

    total $3,006,652 · program services $2,340,984 · management and general $244,851 · fundraising $420,817

  • 7 , Other salaries and wages

    total $6,725,017 · program services $4,377,694 · management and general $650,872 · fundraising $1,696,451

  • 8 , Pension plan contributions

    total $218,687 · program services $140,736 · management and general $22,923 · fundraising $55,028

  • 9 , Other employee benefits

    total $711,707 · program services $475,173 · management and general $70,211 · fundraising $166,323

  • 10 , Payroll taxes

    total $728,372 · program services $501,058 · management and general $67,553 · fundraising $159,761

  • 11a , Fees: management

    total $273,600 · program services $248,248 · management and general $1,995 · fundraising $23,357

  • 11b , Fees: legal

    total $332,090 · program services $301,319 · management and general $2,421 · fundraising $28,350

  • 11c , Fees: accounting

    total $55,750 · program services $50,585 · management and general $406 · fundraising $4,759

  • 11g , Fees: other

    total $4,690,446 · program services $3,637,126 · management and general $95,118 · fundraising $958,202

  • 12 , Advertising and promotion

    total $1,674,634 · program services $1,364,548 · management and general $12,210 · fundraising $297,876

  • 13 , Office expenses

    total $1,445,254 · program services $974,505 · management and general $2,751 · fundraising $467,998

  • 14 , Information technology

    total $1,378,532 · program services $1,250,798 · management and general $10,051 · fundraising $117,683

  • 16 , Occupancy

    total $207,168 · program services $187,972 · management and general $1,510 · fundraising $17,686

  • 17 , Travel

    total $616,552 · program services $396,185 · management and general $10,768 · fundraising $209,599

  • 19 , Conferences, conventions and meetings

    total $724,594 · program services $365 · fundraising $724,229

  • 22 , Depreciation, depletion and amortization

    total $446,265 · program services $420,250 · management and general $7,900 · fundraising $18,115

  • 23 , Insurance

    total $162,738 · program services $147,659 · management and general $1,187 · fundraising $13,892

  • 24a , Other expenses: CLINICAL TRIAL/RESEARCH

    total $6,125,403 · program services $6,125,403

  • 26 , Joint costs (an allocation of the lines above)

    total $299,362 · program services $149,251 · management and general $0 · fundraising $150,111

Balance sheet

Part X, book values.

  • 1 , Cash, non-interest-bearing

    beginning of year $1,373,960 · end of year $2,850,860

  • 2 , Savings and temporary cash investments

    beginning of year $3,484,634 · end of year $6,236,082

  • 3 , Pledges and grants receivable

    beginning of year $3,195,258 · end of year $4,254,361

  • 4 , Accounts receivable

    beginning of year $3,739,397 · end of year $1,327,848

  • 9 , Prepaid expenses and deferred charges

    beginning of year $715,352 · end of year $487,968

  • 10a , Land, buildings and equipment: cost or other basis

    $4,356,947

  • 10b , Land, buildings and equipment: accumulated depreciation

    $2,318,052

  • 10c , Land, buildings and equipment, net

    beginning of year $2,637,698 · end of year $2,038,895

  • 11 , Investments: publicly traded securities

    beginning of year $48,157,559 · end of year $28,979,841

  • 13 , Investments: program-related

    beginning of year $16,363,985 · end of year $19,702,733

  • 15 , Other assets

    beginning of year $559,789 · end of year $518,560

  • 17 , Accounts payable and accrued expenses

    beginning of year $19,417,597 · end of year $11,501,089

  • 18 , Grants payable

    beginning of year $980,000 · end of year $2,407,188

  • 19 , Deferred revenue

    beginning of year $2,808,555 · end of year $1,974,951

  • 25 , Other liabilities

    beginning of year $736,056 · end of year $491,527

  • 27 , Net assets without donor restrictions

    beginning of year $53,786,450 · end of year $46,293,816

  • 28 , Net assets with donor restrictions

    beginning of year $2,498,974 · end of year $3,728,577

Mission and programs · 2024

Mission

SEE SCHEDULE O

  • THE MMRC IS A NETWORK OF 14 LEADING CANCER CENTERS AND ADDRESSES THREE CRITICAL AREAS OF UNMET NEEDS: HIGH-RISK SMOLDERING MYELOMA, HIGH-RISK UPFRONT TREATMENT FOR SYMPTOMATIC MULTIPLE MYELOMA, AND RELAPSED/REFRACTORY TREATMENT AFTER ANTI-CD38 AND BCMA-DIRECTED THERAPIES.IN 2024, THE MMRF LAUNCHED THE HORIZON CLINICAL TRIALS PROGRAM THROUGH THE MMRC, BEGINNING IN PATIENTS WITH RELAPSED AND REFRACTORY MYELOMA TO OPTIMIZE THE USE OF CURRENTLY AVAILABLE AND NEW TREATMENTS, WITH THE GOAL OF MAXIMIZING EFFICACY WHILE MINIMIZING SIDE EFFECTS. IN NOVEMBER, THE FIRST PATIENT WAS ENROLLED IN THE FIRST ARM OF THE HORIZON CLINICAL TRIALS PROGRAM, HORIZON ONE, WHICH WILL ASSESS DOSING APPROACHES WITH TECVAYLI (TECLISTAMAB). THIS FIRST ARM IS DESIGNED TO DETERMINE WHETHER THIS TREATMENT CAN BE GIVEN LESS FREQUENTLY OR EVEN STOPPED ENTIRELY. THE HORIZON CLINICAL TRIALS PROGRAM USES AN ADAPTIVE PLATFORM DESIGN, WHICH MAKES IT POSSIBLE TO TEST MULTIPLE THERAPIES AT THE SAME TIME, TO DETERMINE THE BEST COMBINATION, SEQUENCE, AND DURATION OF TREATMENT TO IMPROVE PATIENT OUTCOMES. WITH THIS DESIGN AND MULTI-INSTITUTIONAL COOPERATION, HORIZON IS UNIQUELY POSITIONED TO ADDRESS RESEARCH QUESTIONS THAT OTHER TYPES OF TRIALS ARE NOT EQUIPPED TO INVESTIGATE.

    Expenses $7,012,440 · Grants $725,000 · Revenue $2,261,716

  • THE MAC PROGRAM PROVIDES $21 MILLION OVER 3 YEARS TO CREATE MULTICENTER TRANSLATIONAL RESEARCH TEAMS ACROSS GLOBAL MEDICAL CENTERS. EACH OF THESE THREE-YEAR MULTICENTER TRANSLATIONAL PROJECTS AIM TO FOSTER COLLABORATION AND ADVANCE COMPELLING HYPOTHESES THAT ARE READY FOR RAPID TESTING IN CLINICAL TRIALS, A CRITICAL STEP IN THE MMRF'S URGENT PURSUIT OF A CURE FOR EACH AND EVERY MYELOMA PATIENT. THE GRANTS ARE FOCUSED ON TWO CRITICAL AREAS OF UNMET NEED: OPTIMIZING FIRST-LINE THERAPY FOR NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA AND IMPROVING IDENTIFICATION OF HIGH-RISK SMOLDERING MULTIPLE MYELOMA (HR SMM), AN EARLY, ASYMPTOMATIC STAGE THAT CAN PROCEED TO ACTIVE MULTIPLE MYELOMA. IN 2024 THE COLLABORATING CENTERS CONTINUED TO MAKE POSITIVE PROGRESS, SHOWING THAT POOLING RESOURCES AND SAMPLES ACROSS A NETWORK OF INSTITUTIONS DRAMATICALLY IMPROVES THE ABILITY TO DRIVE MEANINGFUL RESULTS.

    Expenses $5,400,000

  • THE IMMUNE ATLAS PROGRAM IS A COLLABORATION BETWEEN THE MMRF AND FIVE LEADING ACADEMIC MEDICAL CENTERS. THE MMRF CONTINUED TO BUILD OUT THE MMRF IMMUNE ATLAS INITIATIVE (THE "ATLAS"), AN IMMUNE PROFILING AND ANALYTICS PLATFORM USING DATA AND SAMPLES FROM THE COMMPASS STUDY TO GENERATE DATA ON THE ROLE OF PATIENT IMMUNITY IN MYELOMA DISEASE BIOLOGY AND RESPONSE TO THERAPY, AND TO SUPPORT AND SPEED EFFORTS TO MAKE IMMUNOTHERAPY MORE PRECISE FOR MYELOMA PATIENTS. THE ATLAS DESCRIBES THE IMMUNE LANDSCAPE IN MYELOMA AND HOW IT CHANGES THROUGHOUT THE COURSE OF THE DISEASE AND TREATMENT. THIS EFFORT IS A CRITICAL FIRST STEP TO ESTABLISH GUIDELINES AND ALIGNMENT ON HOW IMMUNE DATA IS PRODUCED, PRIORITIZED, AGGREGATED, AND SHARED. AT SCALE, IT HAS THE POTENTIAL TO IDENTIFY NEW IMMUNOLOGIC FACTORS PREDICTIVE OF PATIENT RESPONSE OR RELAPSE TO THERAPY, TO IDENTIFY NEW IMMUNE TARGETS FOR DRUG DEVELOPMENT AND, EVENTUALLY, ENABLE CLINICIANS TO CUSTOMIZE TREATMENTS AND THERAPIES BASED ON AN INDIVIDUAL'S IMMUNE SYSTEM. IN SEPTEMBER 2024, THE MMRF PRESENTED DATA FROM THE ATLAS AT THE 21ST INTERNATIONAL MYELOMA SOCIETY ANNUAL MEETING IN RIO DE JANEIRO, BRAZIL, WHICH REINFORCED THE VALUE OF THE MMRF'S INTEGRATED CLINICAL AND TRANSLATIONAL CAPABILITIES

    Expenses $1,069,290

  • BEYOND THE PROGRAM EXPENSES OUTLINED ABOVE, THE MMRF ALSO SUPPORTS A RANGE OF STRATEGIC INITIATIVES ALIGNED WITH ITS BROADER MISSION. THIS INCLUDES A ROBUST PORTFOLIO OF CUTTING-EDGE BASIC SCIENCE RESEARCH AIMED AT IDENTIFYING NEW THERAPEUTIC TARGETS THROUGH GENOMICS AND PROTEOMICS; VALIDATION STUDIES TO EXPLORE PROMISING COMPOUNDS AND TREATMENT COMBINATIONS; AND INNOVATIVE CLINICAL TRIALS FOCUSED ON NOVEL AND COMBINATION THERAPIES.FOUNDED BY PATIENTS, THE MMRF IS DEEPLY COMMITTED TO THOSE IMPACTED BY MULTIPLE MYELOMAPATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF DISTINGUISHES ITSELF THROUGH ITS BOLD AND COLLABORATIVE APPROACH. WE GENERATE, ANALYZE, AND SHARE THE LARGEST, MOST COMPREHENSIVE SET OF HIGH-QUALITY MYELOMA DATA, MAKING IT PUBLICLY AVAILABLE TO ACCELERATE PROGRESS. BY BRINGING TOGETHER THE RIGHT PEOPLE, PROGRAMS, AND TECHNOLOGIES, THE MMRF IS DRIVING THE RAPID DISCOVERY OF CURES FOR EACH AND EVERY PATIENT.

    Expenses $15,539,754 · Grants $5,355,876 · Revenue $500,620

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Kathy Giusti

    FOUNDER & DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Thomas Conheeney

    CHAIRMAN

    Total calculated
    $0
    Hours/week
    2
  • Gerald McDougall

    VICE CHAIRMAN

    Total calculated
    $0
    Hours/week
    2
  • Kenneth Anderson MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Karen Andrews

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Rodney Gilmore

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • David Lucchino

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Lori Tauber-Marcus

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Hugh Martin

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Susan Marvin

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • William McKiernan

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Michael Mortimer

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • David Parkinson MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Marie Pinizzotto MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Adrian Rosenkranz

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Steve Shak MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Kimberly White

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2
  • Michael Andreini

    PRESIDENT & CEO

    Total calculated
    $492,322
    From this org
    $466,042
    From related orgs
    $0
    Other
    $26,280
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $389,870
    Bonus
    $75,800
    Other
    $372
    Deferred
    $13,800
    Nontaxable benefits
    $12,480
    Filer's total
    $492,322
  • Robert Miani

    TREASURER & CFO, THRU JUNE 2024

    Total calculated
    $341,915
    From this org
    $328,624
    From related orgs
    $0
    Other
    $13,291
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $124,868
    Bonus
    $56,400
    Other
    $147,356
    Deferred
    $7,292
    Nontaxable benefits
    $5,999
    Filer's total
    $341,915
  • Karen Dietz

    SECRETARY, CAO & GENERAL COUNSEL

    Total calculated
    $297,717
    From this org
    $259,764
    From related orgs
    $0
    Other
    $37,953
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $207,033
    Bonus
    $31,400
    Other
    $21,331
    Deferred
    $10,920
    Nontaxable benefits
    $27,033
    Filer's total
    $297,717
  • Alan Heitner

    TREASURER & CFO, AS OF OCT. 2024

    Total calculated
    $48,231
    From this org
    $46,379
    From related orgs
    $0
    Other
    $1,852
    Hours/week
    40
  • Anne Quinn Young

    CHIEF MISSION OFFICER

    Total calculated
    $353,857
    From this org
    $335,322
    From related orgs
    $0
    Other
    $18,535
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $280,147
    Bonus
    $39,000
    Other
    $16,175
    Deferred
    $13,537
    Nontaxable benefits
    $4,998
    Filer's total
    $353,857
  • George Mulligan

    CHIEF SCIENTIFIC OFFICER

    Total calculated
    $387,816
    From this org
    $342,276
    From related orgs
    $0
    Other
    $45,540
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $300,450
    Bonus
    $40,500
    Other
    $1,326
    Deferred
    $13,800
    Nontaxable benefits
    $31,740
    Filer's total
    $387,816
  • Christopher Williams

    VP OF ALLIANCE MANAGEMENT

    Total calculated
    $254,973
    From this org
    $218,145
    From related orgs
    $0
    Other
    $36,828
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $196,588
    Bonus
    $7,500
    Other
    $14,057
    Deferred
    $9,140
    Nontaxable benefits
    $27,688
    Filer's total
    $254,973
  • Hearn Cho

    CHIEF MEDICAL OFFICER

    Total calculated
    $212,368
    From this org
    $204,200
    From related orgs
    $0
    Other
    $8,168
    Hours/week
    32

    Schedule J breakdown matched by us

    Base
    $175,025
    Bonus
    $23,500
    Other
    $5,675
    Deferred
    $8,168
    Nontaxable benefits
    $0
    Filer's total
    $212,368
  • Stephanie Oestreich

    MANAGING DIRECTOR, MIF

    Total calculated
    $364,631
    From this org
    $337,767
    From related orgs
    $0
    Other
    $26,864
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $298,622
    Bonus
    $12,200
    Other
    $26,945
    Deferred
    $13,540
    Nontaxable benefits
    $13,324
    Filer's total
    $364,631
  • Katie Wozniak

    VP OF CLINICAL RESEARCH

    Total calculated
    $256,808
    From this org
    $218,889
    From related orgs
    $0
    Other
    $37,919
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $199,180
    Bonus
    $14,000
    Other
    $5,709
    Deferred
    $6,892
    Nontaxable benefits
    $31,027
    Filer's total
    $256,808
  • Greg Rubenstein

    VP OF MARKETING

    Total calculated
    $250,587
    From this org
    $210,723
    From related orgs
    $0
    Other
    $39,864
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $185,013
    Bonus
    $13,500
    Other
    $12,210
    Deferred
    $8,863
    Nontaxable benefits
    $31,001
    Filer's total
    $250,587
  • Joanne Puglia

    SR DIRECTOR FINANCE, CONTROLLER

    Total calculated
    $206,732
    From this org
    $197,545
    From related orgs
    $0
    Other
    $9,187
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $174,170
    Bonus
    $13,900
    Other
    $9,475
    Deferred
    $7,864
    Nontaxable benefits
    $1,323
    Filer's total
    $206,732
  • Mark Hamilton

    ASSOCIATE DIRECTOR, RESEARCH

    Total calculated
    $256,969
    From this org
    $244,473
    From related orgs
    $0
    Other
    $12,496
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $216,380
    Bonus
    $17,000
    Other
    $11,093
    Deferred
    $7,700
    Nontaxable benefits
    $4,796
    Filer's total
    $256,969
  • Brian Hochberg

    PRINCIPAL GIFT OFFICER

    Total calculated
    $212,892
    From this org
    $177,081
    From related orgs
    $0
    Other
    $35,811
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $156,134
    Bonus
    $8,000
    Other
    $12,947
    Deferred
    $7,487
    Nontaxable benefits
    $28,324
    Filer's total
    $212,892
  • Heather Steiger

    SR DIRECTOR DIGITAL MARKETING

    Total calculated
    $199,778
    From this org
    $175,571
    From related orgs
    $0
    Other
    $24,207
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $159,577
    Bonus
    $8,400
    Other
    $7,594
    Deferred
    $0
    Nontaxable benefits
    $24,207
    Filer's total
    $199,778

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Form 990 of other organizations
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 4a · Severance or change-of-control payment
  • 7 · Other non-fixed payments

Answered no

  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 4A
ROBERT MIANI, TREASURER & CFO, RECEIVED A SEVERANCE PAYMENT OF $146,800 INCLUDED IN HIS 2024 FORM W-2.
PART I, LINE 7
INDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2024, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2024 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
0
Employees, agents and contractors (line 3c)
0
Expenditures and investments (line 3c)
$2,792,954

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Activities by region (Part I)
Region Offices Employees Activity Specific services Expenditures
EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING — $750,000
MIDDLE EAST AND NORTH AFRICA 0 0 INVESTMENTS — $1,042,959
NORTH AMERICA 0 0 INVESTMENTS — $999,995

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Grants to organizations, by region (Part II)
Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
EUROPE (INCLUDING ICELAND & GREENLAND) $750,000 WIRE $0 — —
Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
1
Other grantees (Part II line 3)
0
Transferred property to a foreign corporation during the year (line 1)
Yes
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
Yes
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Disregarded entities

Part I: entities that legally are the filer and file no return of their own.

  • MYELOMA INVESTMENT FUND LLC

    VENTURE PHILANTHROPY FUND · DE · income $1,301,178 · assets $22,403,440

    Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

  • MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC

    FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH · CT · income $7,842,093 · assets $1,446,240

    Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

Provenance

Return type
form_990
Tax year
2024
Filed
15 October 2025
IRS schema version
2024v5.2
Source object
202512889349301411

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.